PMID- 33675071
OWN - NLM
STAT- MEDLINE
DCOM- 20211123
LR  - 20240102
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 35
IP  - 5
DP  - 2021 May
TI  - Low expression of tRF-Pro-CGG predicts poor prognosis in pancreatic ductal 
      adenocarcinoma.
PG  - e23742
LID - 10.1002/jcla.23742 [doi]
LID - e23742
AB  - BACKGROUND & AIMS: tRFs (tRNA-derived RNA fragments) have been reported to 
      facilitate cancer progression in multiple cancers. However, their role in 
      pancreatic ductal adenocarcinoma (PDAC) remains to be determined. In this study, 
      we mainly investigated the expression of tRF-Pro-CGG in pancreatic ductal 
      adenocarcinoma and evaluated its relationship with the clinicopathology and 
      survival time of patients. METHODS: 37 cases of pancreatic ductal adenocarcinoma, 
      and 15 cases of normal pancreatic tissues were collected which were resected by 
      surgery from January 2017 to June 2020 from the Department of Hepatobiliary and 
      Pancreatic surgery of Changzhou second people's Hospital. The expression of 
      tRF-Pro-CGG in paraffin-embedded tissues was detected by fluorescence in situ 
      hybridization (FISH). The clinical data including age, sex, tumor location, tumor 
      diameter, tumor clinical stage (TNM stage), depth of invasion, regional lymph 
      node metastasis, serum CA199, and serum CEA were collected and analyzed 
      retrospectively, whether the expression tRF-Pro-CGG was correlation with the 
      pathological parameters and clinical outcomes of patients. RESULTS: The 
      expression level of tRF-Pro-CGG was significantly downregulated in PDAC and 
      associated with an advanced TNM stage (P=0.000) and the N stage (P=0.000) of 
      patients. More importantly, low tRF-Pro-CGG expression predicted poor survival in 
      PDAC patients (P=0.003). CONCLUSIONS: TRF-Pro-CGG is under-expressed in PDAC and 
      is associated with short clinical survival and poor prognosis. tRF-Pro-CGG is an 
      independent prognostic factor, which highlights its role as a potential biomarker 
      for PDAC progression and therapy.
CI  - (c) 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley 
      Periodicals LLC.
FAU - Li, Jun
AU  - Li J
AD  - Dalian Medical University, Dalian, China.
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Jin, Lei
AU  - Jin L
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Gao, Yuan
AU  - Gao Y
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Gao, Peng
AU  - Gao P
AD  - Dalian Medical University, Dalian, China.
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Ma, Le
AU  - Ma L
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Zhu, Bei
AU  - Zhu B
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Yin, Xu
AU  - Yin X
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Sui, Shizhen
AU  - Sui S
AD  - Dalian Medical University, Dalian, China.
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Chen, Shuai
AU  - Chen S
AD  - Dalian Medical University, Dalian, China.
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
FAU - Jiang, Zijian
AU  - Jiang Z
AD  - Dalian Medical University, Dalian, China.
FAU - Zhu, Chunfu
AU  - Zhu C
AUID- ORCID: 0000-0002-4363-5781
AD  - Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, Changzhou, China.
LA  - eng
GR  - ZD202023/Major Science and Technology Program of Changzhou Health Commission in 
      2020/
GR  - CCX201807/Changzhou Medical Innovation Team Project/
PT  - Journal Article
DEP - 20210306
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 9014-25-9 (RNA, Transfer)
SB  - IM
MH  - Adenocarcinoma/diagnosis/genetics/pathology
MH  - Base Sequence
MH  - Carcinoma, Pancreatic Ductal/diagnosis/genetics/pathology
MH  - Disease-Free Survival
MH  - Down-Regulation/genetics
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - Pancreatic Neoplasms/diagnosis/genetics/pathology
MH  - Prognosis
MH  - RNA, Transfer/*genetics/metabolism
MH  - ROC Curve
PMC - PMC8128309
OTO - NOTNLM
OT  - fluorescence in situ hybridization
OT  - pancreatic ductal adenocarcinoma
OT  - tRF-Pro-CGG
COIS- The authors declare that this research is not related to any commercial or 
      financial interests.
EDAT- 2021/03/07 06:00
MHDA- 2021/11/24 06:00
PMCR- 2021/03/06
CRDT- 2021/03/06 05:44
PHST- 2021/01/29 00:00 [revised]
PHST- 2021/01/04 00:00 [received]
PHST- 2021/02/10 00:00 [accepted]
PHST- 2021/03/07 06:00 [pubmed]
PHST- 2021/11/24 06:00 [medline]
PHST- 2021/03/06 05:44 [entrez]
PHST- 2021/03/06 00:00 [pmc-release]
AID - JCLA23742 [pii]
AID - 10.1002/jcla.23742 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2021 May;35(5):e23742. doi: 10.1002/jcla.23742. Epub 2021 Mar 6.